Shelly Xiong
Profile
Shelly Xiong worked as a Director of China Operations at Labcorp Drug Development, Inc. and as a Director of Regulatory Affairs at InterMune, Inc. She also worked as a Vice President of Regulatory Affairs at Eiger BioPharmaceuticals, Inc. twice.
Dr. Xiong received her undergraduate degree from Peking University and her doctorate degree from the University of Wisconsin.
Former positions of Shelly Xiong
| Companies | Position | End |
|---|---|---|
| COVANCE INC. | Corporate Officer/Principal | - |
| EIGER BIOPHARMACEUTICALS, INC. | General Counsel | - |
| INTERMUNE INC | General Counsel | - |
Eiger BioPharmaceuticals, Inc. /Old/
 Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | General Counsel | - |
Training of Shelly Xiong
| University of Wisconsin | Doctorate Degree |
| Peking University | Undergraduate Degree |
Experiences
Positions held
Linked companies
| Listed companies | 1 |
|---|---|
| EIGER BIOPHARMACEUTICALS, INC. | Health Technology |
| Private companies | 3 |
|---|---|
Eiger BioPharmaceuticals, Inc. /Old/
Eiger BioPharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Eiger BioPharmaceuticals, Inc. provides pharmaceutical products. It operates as a biopharmaceutical company, which focuses on the discovery and development of new antiviral agents against novel targets in the treatment of hepatitis. The firm’s pipeline includes clinical stage assets and preclinical new chemical entities (NCEs) shown to possess antiviral activity against Hepatitis C, Hepatitis D, and a wide array of other viruses. It also conducts multiple clinical proofs of concept studies in multiple clinical sites in HCV and HDV patients. The company was founded by Jeffrey S. Glenn in 2008 and is headquartered in Palo Alto, CA. | Health Technology |
InterMune, Inc.
 InterMune, Inc. BiotechnologyHealth Technology InterMune, Inc. operates as a biotechnology company that researches, develops and commercializes therapies in pulmonology and orphan fibrotic diseases. It focuses on therapies for the treatment of idiopathic pulmonary fibrosis, a progressive and fatal lung disease. The firms research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor serious pulmonary and fibrotic diseases. The company was founded in 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Labcorp Drug Development, Inc.
 Labcorp Drug Development, Inc. Pharmaceuticals: MajorHealth Technology Covance, Inc. operates as a contract research organization and drug development company. Its services include research, lead optimization, analysis services, safety assessment and drug safety testing, consulting and partnering, clinical development, informatics, clinical testing, commercialization, and manufacturing support. The company was founded on November 12, 1996 and is headquartered in Princeton, NJ. | Health Technology |
- Stock Market
- Insiders
- Shelly Xiong
